Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Teneobio, TESARO Enter Collaboration Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Teneobio, TESARO Enter Collaboration Agreement

To develop novel multi-specific antibodies for up to six undisclosed oncology targets

By: Betsy Louda

, Contract Pharma

Teneobio, Inc. has entered into a research collaboration and licensing agreement with TESARO, Inc. to develop novel multi-specific antibodies for up to six undisclosed oncology targets. 


Under the terms of the agreement, Teneobio will generate product candidates using its proprietary UniRat transgenic human antibody ‘heavy-chain only’ rodent platform and its state-of-the-art sequence-based discovery engine, TeneoSeek. TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.  

 

Teneobio will receive an upfront of $10 million and is eligible for research fees and up to $50M in development milestones per product. They can also receive royalties on world–wide net sales of each multi-specific product. 

 

Roland Buelow, chief executive officer of Teneobio, added, “We are excited to embark on a productive research collaboration with TESARO. Complementing our internal pipeline, our strategic alliance with TESARO further leverages the bandwidth and efficiency of Teneobio’s state-of-the-art discovery platforms to advance specific biotherapeutics to the clinic.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics